What is Appia Bio?
Founded in 2020, Appia Bio operates at the intersection of synthetic biology and clinical oncology. The company specializes in the discovery and development of engineered allogeneic cell therapies, utilizing a scalable technology platform designed to enhance therapeutic efficacy while reducing the complexity of patient-specific manufacturing. By focusing on allogeneic approaches, Appia Bio addresses the critical need for standardized, readily available treatments that can be deployed across broad patient populations. This market position is supported by a robust intellectual property strategy and a focus on high-impact therapeutic areas, positioning the firm as a key player in the next generation of immunotherapy innovation.
How much funding has Appia Bio raised?
Appia Bio has raised a total of $52M across 1 funding round:
Series A
$52M
Series A (2021): $52M with participation from Two Sigma Ventures, Freeflow Ventures, 8VC, and Sherpa Healthcare Partners
Key Investors in Appia Bio
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth and computing power, with a specific focus on breakthrough therapies and data-driven innovation.
8VC
8VC is a leading technology investment firm that manages significant committed capital, focusing on smart enterprise platforms across industries including healthcare and Bio-IT.
Freeflow Ventures
Freeflow Ventures is a venture capital firm that partners with early-stage companies to provide the strategic resources and capital necessary to scale complex technological and scientific breakthroughs.
What's next for Appia Bio?
With this major enterprise-level funding, Appia Bio is expected to prioritize the expansion of its research and development pipeline and the optimization of its manufacturing processes. The strategic roadmap likely includes advancing lead candidates toward clinical trials and strengthening its internal data science capabilities to refine cell engineering protocols. As the company scales, it will likely focus on establishing strategic partnerships to validate its platform's utility in diverse clinical settings. The backing from prominent venture firms suggests a long-term commitment to building a sustainable, high-growth biotechnology enterprise capable of disrupting traditional cell therapy paradigms.
See full Appia Bio company page
